GlassScriptPhysician profile
Cynthia Abbott Duncan
NPI 1972671634
$5,557.67
in general payments reported to CMS, 2019-2025
24 companies · $1,428 in 2025
The $1,428 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
See the full distribution for Psychiatric/Mental Health (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $641 · 2022: $1,194 · 2023: $1,393 · 2024: $902 · 2025: $1,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,722.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $871.73 | 2021-2025 | Azstarys |
| Abbvie INC. | $867.30 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $453.24 | 2021-2025 | Austedo, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $377.85 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $365.32 | 2022-2025 | Caplyta |
| Neos Therapeutics, LP | $354.44 | 2021-2025 | Adzenys Xr-Odt, Exxua |
| Supernus Pharmaceuticals, INC. | $308.43 | 2022-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $299.18 | 2022-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $259.77 | 2025 | |
| Collegium Pharmaceutical, INC. | $152.32 | 2025 | Jornay Pm |
| Alfasigma USA, INC. | $151.90 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $150.29 | 2022-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $146.73 | 2024-2025 | Auvelity |
| Tris Pharma INC | $145.17 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Sunovion Pharmaceuticals INC. | $144.02 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $123.24 | 2023-2025 | Xelstrym |
| Vanda Pharmaceuticals INC. | $84.59 | 2024-2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $82.90 | 2022-2023 | Quviviq |
| Lundbeck LLC | $78.85 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $41.46 | 2022-2023 | Trintellix |
| Bausch Health US, LLC | $37.44 | 2025 | Aplenzin, Wellbutrin |
| Adlon Therapeutics L.P. | $27.88 | 2021 | |
| Vertical Pharmaceuticals, LLC | $17.77 | 2025 | Relexxii |
| Jazz Pharmaceuticals INC. | $15.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.